Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Ethereum call options due on February 23rd on Deribit are noticeably concentrated, with an exercise price of $2,500

Ethereum call options due on February 23rd on Deribit are noticeably concentrated, with an exercise price of $2,500

2024/02/01 00:53

According to The Block data, Ethereum options trading volume hit a historical high in January. The total trading volume of Ethereum options in January has soared to nearly 20 billion US dollars, of which about 15 billion US dollars came from the activities of Deribit derivatives exchange.

On Deribit, there is a noticeable concentration of bullish Ethereum options due on February 23rd with an execution price of $2,500. There are more than 74,548 outstanding bullish contracts with a nominal value of approximately $172 million.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"Orders remain as expected, but confidence has been re-evaluated." Bank of America: ASML three giants’ cooperation strengthens the long-term High-NA roadmap.

On Tuesday, ASML (ASML.US) became the focus of the market as Bank of America praised the company's additional chip manufacturing equipment supply agreements with TSMC (TSM.US), Intel (INTC.US), and Samsung.

智通财经2026/09/09 08:11
"Orders remain as expected, but confidence has been re-evaluated." Bank of America: ASML three giants’ cooperation strengthens the long-term High-NA roadmap.

Novartis (NVS.US) cardiovascular therapy trial "misfire" drags down Amgen (AMGN.US): stock price plunges to a ten-year low, BMO swiftly downgrades rating

Amgen's stock posted its biggest single-day decline since 2016 on Tuesday, after Novartis announced that a heart disease therapy jointly developed with Ionis Pharmaceuticals suffered a setback in late-stage clinical trials. Meanwhile, BMO downgraded the pharmaceutical giant's rating from "Outperform" to "Market Perform," citing the failure of its candidate drug pelacarsen to meet expectations in its phase III clinical trial.

智通财经2026/09/09 08:11
Novartis (NVS.US) cardiovascular therapy trial "misfire" drags down Amgen (AMGN.US): stock price plunges to a ten-year low, BMO swiftly downgrades rating

NASA contractor Rothe Development rushes to Nasdaq, plans to raise $50 millions

Rothe Development, a contractor that provides engineering and mission operations services to NASA and other federal agencies, filed on Tuesday with the SEC to raise up to $50 million through an initial public offering (IPO).

智通财经2026/09/09 08:11
NASA contractor Rothe Development rushes to Nasdaq, plans to raise $50 millions